Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse.
Location: United States, Massachusetts, Woburn
Total raised: $85M
Investors 5
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Omega Fund... | omegafunds... |
| - | Forbion | forbion.co... |
| - | Atlas Vent... | atlasventu... |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.09.2017 | Series B | $55M | Foresite C... |
| 24.09.2015 | Series A | $30M | - |
Mentions in press and media 18
| Date | Title | Description |
| 02.10.2024 | ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City | Conference to Feature Leading Healthcare Companies and Institutional Investors for 1x1/Small Group Meetings and Panels NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to a... |
| 13.06.2024 | Replimune Announces $100 Million Private Placement Financing | - Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical... |
| 20.04.2024 | The Melanoma Research Foundation to host the New England Miles for Melanoma 5K | New England Miles for Melanoma The Melanoma Research Foundation (MRF) is thrilled to announce one of the first events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, care partners and thriv... |
| 06.03.2024 | Replimune to Present at the American Association for Cancer Research Annual Meeting 2024 | - |
| 05.03.2024 | Replimune to Present at Three Upcoming Investor Conferences | - |
| 03.06.2023 | Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting | /EIN News/ -- Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no progression in responding patients... |
| 07.10.2022 | Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. | WOBURN, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that it h... |
| 01.10.2021 | Replimune : Announces Presentations at the 2021 Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting | WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced four poster presentations at the... |
| 27.08.2021 | AstraZeneca promotes oncology exec to CMO; Pfizer replaces retiring chief dealmaker as war chest expands | Cristian Massacesi The biggest bright spot for AstraZeneca over the last few years has been its work in oncology, as CEO Pascal Soriot has helped shepherd blockbusters Imfinzi, Lynparza, and Calquence, among other cancer med... |
| 07.08.2020 | REPLIMUNE GROUP, INC. Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update | Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 refractory melanoma Pipeline progressing; initial s... |
Show more